BMAL1 and central nervous system cancer: The higher efficacy of 1A‐116 was observed at low BMAL1 expression in glioblastoma cells and a differential OS was found when applying 1A‐116 at Zeitgeber times 12 (ZT 12) to glioma‐bearing nude mice.112